Anosmia Clinical Trial
Official title:
Early N-Acetyl Cysteine Treatment for Head Trauma-induced Anosmia
Verified date | February 2021 |
Source | University of Miami |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will compare administration of N-Acetyl Cysteine (NAC) versus placebo for the treatment of olfactory loss due to head injury. The hypothesis is that treatment with NAC acutely after head injury will result in improved olfactory function
Status | Terminated |
Enrollment | 7 |
Est. completion date | January 7, 2020 |
Est. primary completion date | January 7, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Admitted to Ryder Trauma Center for observation acutely following head injury (i.e. concussion), with documented hyposmia or anosmia by University of Pennsylvania Smell Identification Test (SIT). - Male or female, aged 18 years or older - Provision of signed and dated informed consent form - Stated willingness to comply with all study procedures and availability for the duration of the study - Ability to take oral medication and be willing to adhere to the NAC regimen - For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of NAC administration Exclusion Criteria: - Severe trauma requiring ongoing inpatient treatment beyond 48 hours - Pregnancy (based on urine screening) or lactation - Known allergic reactions to components of NAC, such as Mucomyst - Currently taking nitrates such as nitroglycerine and/or isosorbide regularly - Currently taking azathioprine (Imuran) or cyclophosphamide (Cytoxan) - Known diagnosis of cystinuria (renal condition in which cysteine supplement should be avoided) - Febrile illness within 1 week - Treatment with another investigational drug or other intervention within 3 months - Active sinonasal disease by imaging and/or nasal exam, i.e. rhinosinusitis, nasal polyps - Adults unable to consent - Prisoners, employees or subordinates - Individuals who are not yet adults (infants, children, teenagers). This population is excluded because efficacy has not yet been established in adults. |
Country | Name | City | State |
---|---|---|---|
United States | University Of Miami, Otolaryngology Department | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Miami |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Olfactory Function | Olfactory function will be measured using the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT is a self-administered 40-item test involving microencapsulated (scratch-and-sniff) odors with a forced-choice design. The total score ranges from 0-40 with the higher score indicating better olfactory function. | 4 months | |
Secondary | Quality of Life Questionnaire | Quality of life will be measured using the questionnaire for Olfactory Disorders (QOD). QOD has a total score from 0-75 with the higher score indicating a better quality of life. | 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04964414 -
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05445921 -
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
|
Phase 1/Phase 2 | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Withdrawn |
NCT02179554 -
Does Cardiopulmonary Bypass Change Olfaction?
|
||
Completed |
NCT04957563 -
Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia
|
N/A | |
Completed |
NCT04657809 -
Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia
|
Phase 2 | |
Completed |
NCT04853836 -
Olfactory Disfunction and Co-ultraPEALut
|
Phase 4 | |
Recruiting |
NCT05040659 -
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
|
||
Recruiting |
NCT05562050 -
Characteristics of the Anosmic Olfactory Mucosa
|
||
Completed |
NCT05152030 -
The Clinical Applicability of the 'TIB' Olfactory Test Device
|
||
Recruiting |
NCT05384561 -
Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19
|
N/A | |
Enrolling by invitation |
NCT04764981 -
Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19)
|
N/A | |
Withdrawn |
NCT04408391 -
Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
|
||
Completed |
NCT04361474 -
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
|
Phase 3 | |
Completed |
NCT03990766 -
Smell Changes & Efficacy of Nasal Theophylline
|
Phase 2 | |
Completed |
NCT04797936 -
BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19
|
Phase 4 | |
Recruiting |
NCT04528329 -
Anosmia and / or Ageusia and Early Corticosteroid Use
|
Phase 4 | |
Completed |
NCT04789499 -
Smell in Covid-19 and Efficacy of Nasal Theophylline
|
Phase 2 | |
Recruiting |
NCT04384042 -
Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
|
||
Completed |
NCT04390165 -
Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study
|